News | Patient Positioning Radiation Therapy | September 08, 2017

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatment

Decision based on data involving use of SpaceOAR hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement

September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued Interventional Procedure Guidance (IPG) supporting the use of a hydrogel barrier to reduce the risk of toxicity to surrounding tissue in radiotherapy to treat prostate cancer. The guidance recommends use of hydrogel spacers under "standard arrangements". For a procedure to be recommended for use with standard arrangements (previously called “normal arrangements”), the evidence should be adequate to show safety and efficacy of the procedure both in the long term and short term. NICE’s guidance clearly indicates that this procedure meets the highest evidence standards.

The designation is based in part on three-year follow-up data from a Phase III prospective, randomized clinical trial involving the use of SpaceOAR hydrogel, a technology developed by Augmenix to reduce the risk of rectal injury in men receiving prostate cancer radiation therapy (RT) by acting as a spacer that pushes the rectum away from the prostate during treatment.

The IPG designation positions U.K. radiation oncologists and urologists to offer use of a hydrogel spacer such as SpaceOAR as an option for men with prostate cancer who want to reduce their risk of side effects including rectal toxicity, incontinence and loss of sexual function associated with radiotherapy.

“Radiation therapy has been proven to be a highly effective treatment option for many men with prostate cancer, but in many cases patients are concerned about potential side effects related to rectal toxicity, incontinence or sexual function,” said Prof. Heather Payne, a consultant in clinical oncology at University College Hospital, London. “The IPG designation provides important further validation of the benefits of a hydrogel barrier in reducing the risk of side effects, helping patients to proceed to treatment with greater comfort and confidence.”

SpaceOAR hydrogel reduces rectal injury in men receiving prostate cancer radiation therapy by acting as a spacer – pushing the rectum away from the prostate. This space between organs decreases the radiation dose to the rectum and other organs at risk (OAR). Earlier this year, Augmenix announced published data from their prospective, randomized clinical trial showing that patients treated with SpaceOAR hydrogel prior to prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary and sexual benefits through three years of follow-up.

“Our goal in the management of prostate cancer is to identify the most effective treatment options for each patient, and we always have to keep in mind their concerns about side effects that can affect their health and quality of life,” said Suneil Jain, NMD, senior lecturer and consultant in clinical oncology at Queen’s University Belfast. “With SpaceOAR Hydrogel, we have a proven safe option to help address some of the most important concerns that patients have about radiotherapy, including bowel toxicity and loss of sexual function.”

For more information: www.augmenix.com

Related Content

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...
M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

News | Prostate Cancer | March 05, 2020
March 5, 2020 — Using a combination of...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c